--- title: "Collegium Pharmaceutical (COLL) news: lawsuit and settlement" url: "https://aibio.space/companies/collegium-pharmaceutical/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "COLL lawsuit, settlement and buyback news: Collegium settles Grünenthal patent suit over Nucynta ER generic for $17,000,000. Collegium Pharmaceutical, Inc." --- COLL Collegium Pharmaceutical, Inc. NASDAQ · United States # Collegium Pharmaceutical (COLL) news COLL lawsuit, settlement and buyback news Legal · 2026-10-19 ## [Collegium settles Grünenthal patent suit over Nucynta ER generic for $17,000,000](https://aibio.space/news/collegium-settles-grunenthal-patent-suit-nucynta-er-generic-17-000-000/) The drugmaker ends its Nucynta license and royalties with Grünenthal and gets certain patents assigned to it. Grünenthal has filed a motion to dismiss the New Jersey case. ## Latest Collegium Pharmaceutical news 1. 2026-10-19 Distress [Collegium pays Grünenthal $17,000,000 to settle Nucynta suit and end license](https://aibio.space/news/collegium-pays-grunenthal-17-000-000-settle-nucynta-suit-end-license/) Collegium will pay Grünenthal $17,000,000 to end a February 2026 patent suit and a Nucynta license that carried royalties. The 8-K does not say what those royalties cost the company. 2. 2026-05-12 Mergers [Collegium completes $650 million AZSTARYS acquisition, funded with cash and $300 million term loan](https://aibio.space/news/collegium-completes-650-million-azstarys-acquisition-funded-cash-300/) Collegium paid about $650 million in cash for AZSTARYS, using about $350 million of cash on hand and a $300 million delayed draw term loan. Two senior executives are leaving, and the company may pay up to $135 million more if AZSTARYS hits milestones. 3. 2026-05-12 Mergers [Collegium completes AZSTARYS purchase for about $650 million, raises 2026 guidance](https://aibio.space/news/collegium-completes-azstarys-purchase-about-650-million-raises-2026/) Collegium paid about $650 million in cash for AZSTARYS, using $350 million of its own cash and a $300 million loan draw. Corium Therapeutics may receive up to $135 million more if milestones are met. 4. 2025-12-30 Debt Financing [Collegium closes $980 million syndicated credit facility with Truist Bank as agent](https://aibio.space/news/collegium-closes-980-million-syndicated-credit-facility-truist-bank/) The five-year facility has a $580 million initial term loan, a $300 million delayed draw term loan and a $100 million revolver, with Truist Bank as administrative agent. Collegium used the initial loan to repay its previous term loan in full, including its prepayment premium, which the filing does not size. 5. 2025-12-30 Debt Financing [Collegium closes $980 million syndicated credit facility, repays Pharmakon term loan](https://aibio.space/news/collegium-closes-980-million-syndicated-credit-facility-repays/) The $980 million facility matures in 2030 and includes a $580 million initial term loan, a $300 million delayed draw term loan and a $100 million revolver. The initial term loan repaid about $581 million owed to Pharmakon, so it brought no new cash at closing. 6. 2025-07-07 Financings [Collegium Pharmaceutical authorizes buyback of up to $150 million](https://aibio.space/news/collegium-pharmaceutical-authorizes-buyback-up-150-million/) The board approved the program on July 1, 2025. It runs through December 31, 2026 and will be funded from existing cash on hand, but the 8-K gives no cash balance to measure that against. ## Collegium Pharmaceutical at a glance - **Ticker**: COLL - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $129.5 million ### Related companies - [Fortress Biotech](https://aibio.space/companies/fortress-biotech/) NASDAQ: FBIO - [Ovid Therapeutics](https://aibio.space/companies/ovid-therapeutics/) NASDAQ: OVID - [TETRALOGIC PHARMACEUTICALS CORP](https://aibio.space/companies/tetralogic-pharmaceuticals/) OTC: TLOG - [Nano Mobile Healthcare](https://aibio.space/companies/nano-mobile-healthcare/) OTC: VNTH - [EAGLE PHARMACEUTICALS INC](https://aibio.space/companies/eagle-pharmaceuticals/) OTC: EGRX - [Alpha Teknova](https://aibio.space/companies/alpha-teknova/) NASDAQ: TKNO - [Zeo ScientifiX](https://aibio.space/companies/zeo-scientifix/) OTC: ZEOX - [Corbus Pharmaceuticals Holdings](https://aibio.space/companies/corbus-pharmaceuticals/) NASDAQ: CRBP ### Also on NASDAQ - [Elicio Therapeutics](https://aibio.space/companies/elicio-therapeutics/) ELTX - [TREACE MEDICAL CONCEPTS, INC.](https://aibio.space/companies/treace-medical-concepts/) TMCI - [Tonix Pharmaceuticals Holding](https://aibio.space/companies/tonix-pharmaceuticals/) TNXP - [VivoSim Labs, INC.](https://aibio.space/companies/vivosim-labs/) VIVS - [Cumberland Pharmaceuticals](https://aibio.space/companies/cumberland-pharmaceuticals/) CPIX - [Cosmos Health](https://aibio.space/companies/cosmos-health/) COSM ## Collegium Pharmaceutical annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$780.6 million](https://www.sec.gov/Archives/edgar/data/1267565/000162828026011992/) | [$631.4 million](https://www.sec.gov/Archives/edgar/data/1267565/000162828026011992/) | | Research and development | | [$0](https://www.sec.gov/Archives/edgar/data/1267565/000155837025001801/) | | Net income (loss) | [$62.9 million](https://www.sec.gov/Archives/edgar/data/1267565/000162828026011992/) | [$69.2 million](https://www.sec.gov/Archives/edgar/data/1267565/000162828026011992/) | | Cash from operations | [$329.3 million](https://www.sec.gov/Archives/edgar/data/1267565/000162828026011992/) | [$205.0 million](https://www.sec.gov/Archives/edgar/data/1267565/000162828026011992/) | | Cash and equivalents | [$231.3 million](https://www.sec.gov/Archives/edgar/data/1267565/000162828026053851/) | [$70.6 million](https://www.sec.gov/Archives/edgar/data/1267565/000162828026011992/) | | Short-term investments | [$155.4 million](https://www.sec.gov/Archives/edgar/data/1267565/000162828026053851/) | [$92.2 million](https://www.sec.gov/Archives/edgar/data/1267565/000162828026011992/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $129.5 million, plus short-term investments of $0, $129.5 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Collegium Pharmaceutical Is Collegium Pharmaceutical involved in a lawsuit? Our latest story on this, dated Oct 19, 2026: "Collegium settles Grünenthal patent suit over Nucynta ER generic for $17,000,000". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/collegium-settles-grunenthal-patent-suit-nucynta-er-generic-17-000-000/). Has Collegium Pharmaceutical settled a lawsuit? Our latest story on this, dated Oct 19, 2026: "Collegium settles Grünenthal patent suit over Nucynta ER generic for $17,000,000". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/collegium-settles-grunenthal-patent-suit-nucynta-er-generic-17-000-000/). Does Collegium Pharmaceutical have a share buyback? Our latest story on this, dated Jul 7, 2025: "Collegium Pharmaceutical authorizes buyback of up to $150 million". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/collegium-pharmaceutical-authorizes-buyback-up-150-million/). What is the ticker symbol of Collegium Pharmaceutical? Collegium Pharmaceutical, Inc. trades under the ticker COLL on NASDAQ. Where is Collegium Pharmaceutical listed? Collegium Pharmaceutical, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:354; LS:A14SUV; LSX:A14SUV. What is the SEC CIK of Collegium Pharmaceutical? The SEC Central Index Key (CIK) for Collegium Pharmaceutical, Inc. is 1267565. Its filings are on SEC EDGAR. How many shares does Collegium Pharmaceutical have outstanding? 32,555,613 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is Collegium Pharmaceutical listed under? Our directory records Collegium Pharmaceutical, Inc. under United States. What does Collegium Pharmaceutical do? Our directory classifies Collegium Pharmaceutical, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Collegium Pharmaceutical? The ISIN recorded for Collegium Pharmaceutical, Inc. is US19459J1043. Does aibio.space cover Collegium Pharmaceutical? aibio.space lists Collegium Pharmaceutical, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Collegium Pharmaceutical incorporated? SEC records list its state or country of incorporation as VA. What was Collegium Pharmaceutical's revenue last year? $780.6 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Collegium Pharmaceutical profitable? Collegium Pharmaceutical, Inc. reported net income of $62.9 million for the fiscal year ended Dec 31, 2025, and generated $329.3 million of cash from operations, per its annual report to the SEC. How much cash does Collegium Pharmaceutical have? $129.5 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. ## Investor discussion: Collegium Pharmaceutical Members talk about Collegium Pharmaceutical (COLL). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Collegium Pharmaceutical, newest first. Each line links the filing it comes from. 1. 2026-10-19 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02). [Source](https://www.sec.gov/Archives/edgar/data/1267565/000110465926116876/tm2627827d1_8k.htm) 2. 2026-05-12 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,5.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1267565/000110465926059018/tm2614189d1_ex99-1.htm) 3. 2025-12-30 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,1.02,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1267565/000110465925125026/tm2534421d1_ex99-1.htm) 4. 2025-07-07 Financings Announced a share repurchase program. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1267565/000110465925065981/tm2519449d1_8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:COLL on TradingView](https://www.tradingview.com/symbols/NASDAQ-COLL/). ## SEC filings and registration - **SEC name**: Collegium Pharmaceutical, Inc - **CIK**: 1267565 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: COLL (Nasdaq) - **State or country of incorporation**: VA - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: 100 TECHNOLOGY CENTER DRIVE, STOUGHTON, MA, 02072 - **Phone**: 781-713-3699 - **Shares outstanding**: 32,555,613 as of 2026-07-31 (10-Q filed 2026-08-06) - **Former names**: COLLEGIUM PHARMACEUTICAL INC ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1267565/000110465926116876/tm2627827d1_8k.htm) filed 2026-10-19 - [8-K](https://www.sec.gov/Archives/edgar/data/1267565/000110465926095464/tm2623090d1_8k.htm) filed 2026-08-13 - [10-Q](https://www.sec.gov/Archives/edgar/data/1267565/000162828026053851/coll-20260630.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1267565/000162828026053849/coll-20260806.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1267565/000110465926062536/tm2614189d1_8k.htm) filed 2026-05-15 - [8-K](https://www.sec.gov/Archives/edgar/data/1267565/000110465926059018/tm2614189d1_8k.htm) filed 2026-05-12 - [10-Q](https://www.sec.gov/Archives/edgar/data/1267565/000162828026031697/coll-20260331.htm) filed 2026-05-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1267565/000162828026031694/coll-20260507.htm) filed 2026-05-07 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001267565), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Collegium Pharmaceutical, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker COLL, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Collegium Pharmaceutical, Inc. - **Ticker**: COLL - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US19459J1043 - **Other listed symbols**: GETTEX:354; LS:A14SUV; LSX:A14SUV - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-COLL/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/collegium-pharmaceutical/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Collegium Pharmaceutical (COLL) news: lawsuit and settlement", 2026-10-31, https://aibio.space/companies/collegium-pharmaceutical/